Scarica l'app Stockscreener
7.58
1.68%
-0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Investors to Connect - The National Law Review
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst - TradingView
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect - ACCESS Newswire
ImmunityBio (IBRX) Could Be 37% Below Fair Value Following Revenue Surprise Talk - Sahm
IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst - Stocktwits
ImmunityBio Stock Short Interest Falls to 33.94% - Quiver Quantitative
IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth - Stocktwits
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally - Stocktwits
IBRX Stock Steadies As Director Cheryl Cohen Unloads Shares - StocksToTrade
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout - 24/7 Wall St.
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact - Stocktwits
IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - AOL.com
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
IBRX Stock Slips Overnight: Founder Teases Turkey Push, Says AI Cancer Cell Robot Is ‘Almost There’ - Stocktwits
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11% - Stocktwits
Form 4 Immunitybio Inc For: 6 July By Investing.com - Investing.com Nigeria
ImmunityBio Insider Sold Shares Worth $1,246,941, According to a Recent SEC Filing - Moomoo
ImmunityBio: A Long-Term Bull Case Worth Watching - Seeking Alpha
ImmunityBio Insider Sold Shares Worth $1,439,066, According to a Recent SEC Filing - marketscreener.com
Immunitybio Inc (IBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ImmunityBio (IBRX) director sells 159,478 shares under 10b5-1 plan - Stock Titan
ImmunityBio director Selecky sells $1.44m in shares - Investing.com
ImmunityBio director Cheryl Cohen sells $1.25m in stock By Investing.com - Investing.com Canada
ImmunityBio director Selecky sells $1.44m in shares By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio director Cheryl Cohen sells $1.25m in stock - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Investors to Reach Out - ACCESS Newswire
ImmunityBio (IBRX) Is Up 8.4% After Russell Index Removal Amid Anktiva Expansion EffortsWhat's Changed - simplywall.st
ImmunityBio (NASDAQ:IBRX) Screens as a High-Growth Momentum Stock Passing Minervini’s Trend Template - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Form 144 shows proposed sale of 55,979 shares by Morgan Stanley (IBRX) - Stock Titan
IBRXImmunityBio Inc Revenue Breakdown - Finviz
Director Christobel Selecky Sells 96,722 Shares of ImmunityBio I - GuruFocus
Form 144 IMMUNITYBIO For: 1 July By Investing.com - Investing.com Canada
Form 4 Immunitybio Inc For: 1 July By Investing.com - Investing.com Canada
ImmunityBio director Selecky sells $871k in stock - Investing.com
ImmunityBio director Selecky sells $871k in stock By Investing.com - Investing.com Canada
Immunitybio Insider Sold Shares Worth $871,216, According to a Recent SEC Filing - marketscreener.com
ImmunityBio (IBRX) director pre-plans option exercises and sells 96,722 shares - Stock Titan
Insider files Form 144: IBRX (NASDAQ: IBRX) plans sale of 159,478 shares - Stock Titan
IBRX (NASDAQ) insider exercise 1,000 shares; 95,722-share 10b5-1 sale - Stock Titan
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Connect - ACCESS Newswire
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales - Stocktwits
0.16%
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):